Background and objectives Breast cancer patients are vulnerable to depression with prevalence varying between 11 and 86% in literature with direct and indirect impact on compliance to treatment, quality of life and response to therapeutic course. Our study aims to identifying the profile of patients with cancer breast whom symptoms exceed normal reactive sadness to depressive manifestation necessitating psychiatric and psychological intervention. Methods 100 female patients with breast cancer diagnosis were recruited from Alexandria Police Hospital after consenting they were subject to mammogram, laboratory investigations for calcium, alkaline phosphatase, renal, hepatic functions and complete blood picture and thyroid profile. Hamilton Rating Scale and structured demographic data questionnaire was to collect relevant data. Results The prevalence of moderate to severe depressive symptoms on HAM-D was 52%, Significant statistical association was found between patients with depressive manifestations and postmenopusal state (p<0.001), with widowed and divorced (p<0.001), family history of brease cancer (p<0.001), advanced cancer staging (p<0.001), presence of Infiltrative ductal carcinoma (p<0.001) and type of surgery whether lumbectomy or modifies radical mastectomy (p<0.05). However the presence of brain metastasis, adjuvant chemotherapy or presence of family history of psychiatric illness didn't show statistical difference. Conclusion Depression is a common illness among breast cancer patients with particular vulnerable group among those postmenopausal widowed and divorced with advanced stage having rather infiltrative ductal carcinoma.

Background and Objectives High incidence of osteoporosis and pathological fractures were observed in schizophrenic patients medicated by antipsychotics for long time. Hyperprolactinemia induced by antipsychotics may partially contribute to osteopenia. Though atypical antipsychotics cause less hyperprolactinemia than conventional antipsychotics, however, risperidone and amisulpride seem to have no advantage in this regard. Our study aims at assessing effect of long term use of antipsychotics on bone density. Methods 30 schizophrenic patients on antipsychotics for 2-10 yrs were recruited compared to control drug naïf schizophrenic group for bone mineral density Results: both groups were balanced for age and gender distribution. Significantly decreased bone mineral density was found among schizophrenic patients on long term use of antipsychotics (X 2 =3.25;p<0.05). This later had significantly higher serum prolactin (p<0.001) and lesser serum cortisol level (p<0.01). Conclusion Osteopenia and osteoporosis are common adverse effects among antipsychotics, though can easily be screened for, but it's often a forgotten side effect with impact on general health state.

study the effect of rbST treatment during pre-and postpartum period on live body weight, milk production, composition and lambing rates of crossbred ewes (1/2 Finnish Landrace x 1/2 Rahmani). A total number of 40 mature healthy crossbred ewes (1/2 Finnish Landrace x 1/2 Rahmani) having 3-4 years of age were divided into two similar groups (control and treatment), according to their live body weight (LBW). Ewes in the first group were served as a control group, while those in the second group were treated with a subcutaneous injection of 160 mg recombinant bovine Somatotropin (rbST) at 14-day interval during one-month prepartum and 4 months postpartum. During May mating season, ewes were monitored for sign of oestrus and those observed in heat were natural mating using 4 fertile rams. Milk yield and composition were determined throughout first 8 lactation weeks. Results show that LBW of ewes at prepartum and early postpartum suckling period was not affected by rbST treatment. However, treated ewes were heavier (P<0.05) by about 5% than controls only during late postpartum (breeding season from April to June). Treatment with rbST increased (P<0.05) average daily milk yield of ewes during the 1 st eight weeks of lactation. The magnitude of increase ranged between 16 and 33% during different lactation weeks. Treatment with rbST decreased (P<0.05) contents of fat, protein and in turn total solids in milk of ewes during the first 2 months of lactation. However, lactose and ash contents in milk of ewes were not affected significantly by rbST treatment. Treatment with rbST increased (P<0.05) oestrus/mating rate (40 vs. 70%) and reduced postpartum period of lambing ewes by about one month as compared to untreated ewes (65 vs. 93 days). Lambing rate based on number of mated ewes was significantly (P<0.05) lower in control than in treated ewes (75 vs. 85.7%). In conclusion, injection of 160 mg rbST at 14-day interval during one-month prepartum and 4 months postpartum improved milk yield and lambing rate of ewes.